Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Pembrolizumab (Keytruda®)	TA357 - Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab TA366 - Pembrolizumab for advanced melanoma not previously treated with ipilimumab TA428 - Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy TA519 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy TA522 - Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable TA531 - Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer TA540 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma TA553 - Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer TA661 - Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma TA683 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer TA692 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy TA709 - Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma TA851 - Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer TA904 - Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer TA914 - Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency TA939 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	For hospital use only
Pemetrexed injection	TA190 - Pemetrexed for the maintenance treatment of non-small-cell lung cancer TA181 - Pemetrexed for the first-line treatment of non-small-cell lung cancer TA135 - Pemetrexed for the treatment of malignant pleural mesothelioma TA309 - Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer TA124 - Pemetrexed for the treatment of non-small-cell lung cancer TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer	For hospital use only. Negative TA (124)
Penecillamine tablets		ESCA
Penicillamine		Specialist recommendation for Wilson disease. Supported with an ESCA (in development).
Penicillin 5000 units in 1ml eye drops		Unlicensed. Hospital use only, ophthalmologists.
Pentostatin injection		National CDF list
Peppermint water		Unlicensed
Peptac		First choice
Perampanel tablets		ESCA
Pertuzumab (Perjeta®)	TA569 - Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer	For hospital use only

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.